Dr. Shiv Srivastava is a cancer research scientist, a leader and a mentor who has dedicated nearly four decades of his professional career focused on the frontiers of cancer science for the benefit of patients. He served as the founding Scientific Director of the Center for Prostate Disease Research (CPDR)/Prostate Cancer Center of Excellence at the Uniformed Services University of the Health Sciences (USU) for over 25 years (1993-2018). During this period, he also held the positions of Co-Director and Dr. Judd W. Moul Basic Science Chair at the CPDR and Professor in the Department of Surgery at the USU. He co-led the establishment of the multi-disciplinary basic science and translational research programs in prostate cancer and unique bio-resources at the USU, Walter Reed National Military Medical Center (WRNMMC) and Murtha Cancer Center (MCC). His team’s research has been credited with (1) discovery and translation of prostate cancer driver genes, (2) development or evaluation of technologies for improving diagnosis, prognosis and treatment of prostate cancer, and (3) molecular basis of racial disparity in prostate cancer.

Dr. Srivastava’s graduate school and post-doctoral trainings included PhD from the prestigious Indian Institute of Technology (IIT), Delhi and fellowships at the world leading cancer research centers: Memorial Sloan-Kettering Cancer Center and the National Cancer Institute. Dr. Srivastava embarked on an independent cancer research career in the Washington DC metro area, initially as a faculty member of the Georgetown University-Lombardi Cancer Center, followed by a move to then newly established Tumor Biology Program of the at USU. He spent first five years at the USU building career foundations in inter-disciplinary cancer research, a new paradigm at that time. He then joined the USU-Center for Prostate Disease Research, a translational research center to lead its basic science research arm. Dr. Srivastava pursued the basic and translational cancer science for over three decades at USU.

Dr. Srivastava has dedicated most of his professional career addressing the roles of oncogenes and tumor suppressors in cancer, prostate cancer molecular biology/genetics and building bio-resources for translational research. His research contributions and innovations are reflected in over 200 publications, 375 meeting presentations and 12 issued patents. The discoveries of germ-line mutations of the P53 tumor suppressor gene in Li-Fraumeni Syndrome and ERG as the most prevalent prostate cancer driver oncogene and development of a highly specific ERG monoclonal antibody represent some of the notable landmarks in his career (Srivastava et al, Nature,1990; Petrovics et al, Oncogene, 2005; Sedarsky et al, Nature Reviews Urology, 2018). He has co-directed the funding for the USU-CPDR ($125M+) and has served as the PI on grants and CRADA from the NIH, DoD and Biotechnology/Pharma industry ($15M+). His training/mentoring initiatives have inspired a large cadre of next-generation of bio-medical researchers (250+). He continues to serve the cancer research community as consultant, collaborator, mentor, advisory committee member, and reviewer for leading cancer journals and funding agencies. He remains a strong champion for accelerating research that enhances the precision medicine for cancer patients.